Connect with us

Technologies

Ivermectin and COVID-19: Why poison centers are getting calls about this controversial drug

Is this a miracle pill or a sham?

Since the start of the COVID-19 pandemic, some medical professionals have reviewed already available drugs to see if they could be used as effective treatments. Ivermectin, an anti-parasitic, was administered to some patients across the globe, with seemingly positive effects. However, more studies show it has little to no effect when it comes to treating COVID-19. There’s also been an increase in calls to poison centers by people who are taking ivermectin intended for animals.

On one side, there are doctors who say ivermectin could help end the pandemic if used globally. On the other are public health officials who have reviewed the data and say the drug’s effectiveness against COVID-19 isn’t conclusive.

Here’s everything you need to know about ivermectin and its use for COVID-19.

What is ivermectin?

Ivermectin is an anti-parasitic medicine «that works by altering cellular channels,» said Dr. Soumi Eachempati, CEO of Cleared4 and former professor of surgery and public health at Weill Cornell Medical College. The drug inhibits some viruses from infecting cells, thus preventing the virus from spreading. Ivermectin is usually given to treat parasitic infections like lice and Strongyloides, according to Eachempati.

Scientists at pharmaceuticals giant Merck discovered ivermectin in 1975 and began to use it to treat scabies, river blindness and other parasitic diseases carried by worms and lice starting in 1981. It’s on the World Health Organization’s list of essential medicines for a basic health care system. More than 250 million people take the drug across the globe each year, and it’s effective for animals as well.

The drug is considered safe when taken in appropriate dosages. Side effects for the ivermectin vary depending on whether it’s taken orally to treat intestinal infections or topically for skin infections. Oral tablets can cause drowsiness, nausea, vomiting and, in very rare cases, an increase in heart rate and seizures. Side effects for the topical ivermectin can include skin rash and irritation, while dry skin and stinging pain are severe and rare.

Can ivermectin be used to cure COVID-19?

This is where things get complicated. Public health agencies, including the Federal Drug Administration, the National Institutes of Health and the World Health Organization, don’t suggest ivermectin’s use to treat COVID-19. They cite the lack of data from large, randomized trials confirming the drug’s effectiveness to treat the disease.

Doctors who cited multiple smaller studies and firsthand experience say otherwise. They claim ivermectin does work to prevent people from developing symptoms from COVID-19 and can shorten recovery time for those already infected.

What do the public health agencies say about ivermectin use for COVID-19 treatment?

The FDA said in March it hasn’t approved the use of ivermectin to treat COVID-19. It warned that large doses of the drug are «dangerous and can cause serious harm.» The agency also advised against human use of ivermectin produced for animals, such as cows and horses, as the doses aren’t the same and could contain ingredients intended only for animals.

window.CnetFunctions.logWithLabel(‘%c One Trust ‘, «Service loaded: script_twitterwidget with class optanon-category-5»);

A growing number of people have been taking ivermectin for animals as word’s spread on social media about its possible use against COVID-19. This has resulted in some people calling state poison centers after taking the drug, since the medication is intended for animals. On Aug. 20, the Mississippi State Department of Health sent out an alert regarding the number of calls its poison center received, with 70% related to the «ingestion of livestock or animal formulations of ivermectin purchased at livestock supply centers

In April, the FDA reaffirmed in a post on its website that ivermectin isn’t approved to treat COVID-19 nor has it been given emergency use authorization.

The NIH said in February there was insufficient data to «recommend either for or against the use of ivermectin for the treatment of COVID-19.» It did say lab tests found the drug stopped the reproduction of the SARS-CoV-2 virus that cause the disease. However, to be effective, the dosages would need to be «100-fold higher than those approved for use in humans.»

While some clinical studies showed ivermectin to have no benefit, the NIH said others saw a lower mortality rate among patients. However, those studies were incomplete or had methodological limitations such as small sample sizes or patients receiving additional medicine along with ivermectin, according to the NIH.

The WHO said in March the current evidence on the use of ivermectin for treatment of COVID-19 was «inconclusive.»

A doctor in Arkansas who prescribed the drug to patients is under investigation by the state medical board, according to a report from CNN. He reportedly gave ivermectin prescriptions to prisoners at the county jail where he was contracted to provide medical services.

Who says ivermectin is a treatment, and what information do they have?

Ivermectin’s potential use as a COVID-19 therapeutic made headway last December during a Senate Homeland Security Committee meeting called Focus on Early Treatment of COVID-19. Dr. Pierre Kory, a pulmonary and critical care specialist, testified about the drug’s usage for treatment of the disease.

«Ivermectin is highly safe, widely available, and low cost,» Kory said in the Senate meeting. «We now have data from over 20 well-designed clinical studies, 10 of them randomized, controlled trials, with every study consistently reporting large magnitude and statistically significant benefits in decreasing transmission rates, shortening recovery times, decreasing hospitalizations, or large reductions in deaths. These data show that ivermectin is effectively a ‘miracle drug’ against COVID-19.»

During his testimony, Kory referred to a paper he authored — Review of the Emerging Evidence Demonstrating the Efficacy of Ivermectin in the Prophylaxis and Treatment of COVID-19 — that was published in the May edition of the American Journal of Therapeutics.

The paper was also included in the Frontiers of Pharmacology journal in January but was then removed in March. Dr. Frederick Fenter, chief executive editor of the journal, said the paper was removed due to «strong, unsupported claims based on studies with insufficient statistical significance, and at times, without the use of control groups.» Fender also said the authors promoted their own specific ivermectin-based treatment, which goes against editorial policies.

A study listed in Kory’s paper involved giving ivermectin to 234 uninfected health care workers in Argentina and found those who received the drug were far less likely to be diagnosed with COVID. For mildly ill patients, an Iraq study saw a quicker recovery time.

There are also studies that show otherwise. A clinical trial of 476 patients found ivermectin didn’t improve the recovery time in patients who had COVID-19. A review of 10 random clinical trials, with more than 1,000 participants, also didn’t find improvements with ivermectin. One Egyptian study claimed to show positive results, but it’s since been redacted over ethical concerns. Another study, of 1,500 patients, found that ivermectin had «no effect whatsoever.»

Merck, the company that discovered ivermectin, released a statement in February saying there was «no scientific basis for a potential therapeutic effect against COVID-19 from pre-clinical studies» and «no meaningful evidence for clinical activity or clinical efficacy in patients with COVID-19 disease.» It also cited a lack of safety data from major studies.

Why is there controversy over ivermectin?

The debate about ivermectin’s usage to treat COVID-19 has gone from the hospital to social media, exacerbating the discourse as well as the vitriol. While those in support of the drug appear to want an end to the pandemic, their arguments in favor of ivermectin have become fodder for anti-vaxxers and conspiracy theorists.

Groups that have spread misinformation about COVID-19 throughout the pandemic latched onto ivermectin’s usage following Kory’s Senate testimony. Anti-vax groups on Telegram share misinformation about the vaccine while asking where they can buy the drug. Rumble, an alternative video platform to YouTube, has pages of videos falsely saying vaccines are ineffective while advising people to also take ivermectin.

Anti-vax posts and videos can also be found on YouTube, Facebook and Twitter, although the companies are attempting to take these posts down or make them harder to find.

Kory was a guest on the Dark Horse Podcast hosted by Bret Weinstein, a former professor at Evergreen State College, on June 1 to talk about ivermectin. That video was eventually demonetized on YouTube and Weinstein’s channel received a strike, which prevented him from posting content for one week and could lead to its removal if he receives two more strikes within 90 days.

YouTube says its actions on Weinstein’s videos were part of its policies.

«While we welcome open discussions of potential treatments and clinical trials related to COVID-19 on YouTube, based on guidance from the CDC, FDA and other local health authorities, we don’t currently allow content that recommends ivermectin as an effective treatment or prevention method for the virus,» said Ivy Choi, a YouTube spokesperson. «We craft our policies to prevent the risk of egregious real-world harm, and update them as official guidance evolves. We do allow exceptions to our policy about ivermectin, including content that also gives viewers the full context of the FDA’s current position

Because of YouTube’s decision, the controversy over ivermectin grew and became tied to what some claim to be «big tech censorship.»

What is required for ivermectin to get approved for COVID-19 treatment?

For the public health agencies, it’s going to come down to the results of large clinical studies being conducted around the world.

«In the UK, it was announced that ivermectin will be added to the Principle Trial, a large clinical study designed to assess potential COVID therapies for non-hospitalized therapies for patients at higher risk for severe disease,» said Dr. David Shafran, head of pediatrics at telehealth app K Health. «This should demonstrate more definitively the efficacy of ivermectin in early-stage COVID infections. Fingers crossed because it’s a cheap medication with a good safety profile. It would be great to add this to the armament of medication to fight COVID.»

The Oxford University Principle Trial has more than 5,000 participants and will give a three-day course of oral ivermectin treatment to individuals randomly and compare their results to individuals who will receive standard care.

In the US, the NIH is evaluating therapeutics for COVID-19 with its Accelerating COVID-19 Therapeutic Interventions and Vaccines (ACTIV) master protocol. ivermectin was added in phase three of ACTIV-6, which will test the effectiveness of repurposed drugs.

«The ACTIV prioritization group, trial team and trial oversight groups continuously track new data on any agent we are studying in our trials and evaluate that data for how it might influence our testing of that agent and the safety/well being of the participants in the trial,» said Dr. Sarah Dunsmore, a program director at the National Center for Advancing Translational Sciences that is part of the NIH.

What’s unclear is how long the whole process will take. The studies need time to be completed, and then the agencies will require additional time to come up with decisions based on the data.

Technologies

AI Notification Summaries Come Back to iPhone News Apps, but With a Warning

Apple disabled these summaries for most of 2025.

Apple brought AI notification summaries for news and entertainment apps back to Apple Intelligence-enabled iPhones when the company released iOS 26 in September. Apple disabled these summaries in early 2025 after the BBC pointed out in December 2024 that the feature twisted the media organization’s notifications and displayed inaccurate information.

What’s different now about these summaries is that your device’s settings warn you that the summaries might be inaccurate. Your device will also note that you should verify the information in these summaries, and the best way I can think of to do this is to tap into the notification and read the story. This might defeat the purpose of the summaries for some people, but it could also ensure people read past a headline.

Here’s what to know about those AI summaries and the new warning.


Don’t miss any of our unbiased tech content and lab-based reviews. Add CNET as a preferred Google source.


iOS 26 warns about summary inaccuracies

When I updated to iOS 26, I was greeted by some splash screens asking for various permissions. One splash screen was for the AI notification summaries. When you see this screen, you have two options: Choose Notifications to Summarize or Not Now. If you tap Not Now, the splash screen goes away. 

If you tap Choose Notifications to Summarize, you’re taken to a new page where you’ll see three categories: News & Entertainment, Communication & Social and All Other Apps. Tapping one of these categories allows notification summaries for apps in that category. Beneath the News & Entertainment category, there’s a warning that gets outlined in red if you tap it.

«Summarization may change the meaning of the original headline,» the warning reads, adding, «Verify information.»

There’s also a warning across the bottom of the screen that reads, «This is a beta feature. Summaries may contain errors.»

After tapping the categories you want, tap Summarize Selected Notifications across the bottom of your screen. If you selected all the categories, this button will read Summarize All Notifications.

And if you don’t want these summaries, you can tap Do Not Summarize Notifications. If you allow these summaries and don’t like them, you can easily turn them off. Here’s how.

How to turn off AI notification summaries

1. Tap Settings
2. Tap Notifications.
3. Tap Summarize Notifications.

4. Tap the Summarize Notifications toggle in the new menu.

You can also follow the above steps to turn AI notification summaries back on. You’ll have to select which categories you want these summaries for again, too. 

For more iOS news, here’s what to know about iOS 26.2 and what was included in iOS 26.1. You can also check out our iOS 26 cheat sheet for other tips and tricks.

Continue Reading

Technologies

Today’s NYT Connections: Sports Edition Hints and Answers for Jan. 7, #471

Here are hints and the answers for the NYT Connections: Sports Edition puzzle for Jan. 7, No. 471.

Looking for the most recent regular Connections answers? Click here for today’s Connections hints, as well as our daily answers and hints for The New York Times Mini Crossword, Wordle and Strands puzzles.


Today’s Connections: Sports Edition is a bit tricky. The blue category was a real stumper for me, though I found the purple group easy today for a change. If you’re struggling with today’s puzzle but still want to solve it, read on for hints and the answers.

Connections: Sports Edition is published by The Athletic, the subscription-based sports journalism site owned by The Times. It doesn’t appear in the NYT Games app, but it does in The Athletic app. Or you can play it for free online.

Read more: NYT Connections: Sports Edition Puzzle Comes Out of Beta

Hints for today’s Connections: Sports Edition groups

Here are four hints for the groupings in today’s Connections: Sports Edition puzzle, ranked from the easiest yellow group to the tough (and sometimes bizarre) purple group.

Yellow group hint: On the ice.

Green group hint: Run and jump.

Blue group hint: Baseball bosses.

Purple group hint: Golden State schools.

Answers for today’s Connections: Sports Edition groups

Yellow group: NHL teams with singular nicknames

Green group: A bit of track and field equipment.

Blue group: MLB managers.

Purple group: Mascots for University of California schools in the singular.

Read more: Wordle Cheat Sheet: Here Are the Most Popular Letters Used in English Words

What are today’s Connections: Sports Edition answers?


Don’t miss any of our unbiased tech content and lab-based reviews. Add CNET as a preferred Google source.


The yellow words in today’s Connections

The theme is NHL teams with singular nicknames. The four answers are Avalanche, Kraken, Lightning and Mammoth.

The green words in today’s Connections

The theme is a bit of track and field equipment. The four answers are baton, hurdle, javelin and pole.

The blue words in today’s Connections

The theme is MLB managers. The four answers are Cash, Counsell, Marmol and Vogt.

The purple words in today’s Connections

The theme is mascots for University of California schools, in the singular. The four answers are Banana Slug, Bruin, Gaucho and Golden Bear.

Continue Reading

Technologies

Yes, This Swimming RoboTurtle Is Adorable. It Also Has an Important Environmental Mission

Beatbot is best known for making pool-cleaning robots, but it was its swimming robot turtle that won our hearts at CES 2026.

Few things in life have made me feel more privileged and awestruck than the opportunity to swim with sea turtles in their natural environment. The way in which these gentle creatures navigate through their underwater world with their deliberate and careful fin strokes is utterly mesmerizing to watch.

It’s a distinctive style of movement — so much so that when I saw Beatbot’s RoboTurtle swim across a water tank on the show floor at CES 2026, I knew that this wasn’t simply just a pool cleaner robot with turtle features tacked on. This was a studied example of biomimicry in action.

The reason for this is that the company’s engineers went on a two-month expedition to study sea turtles in their natural environment, Beatbot’s Eduardo Campo told me as we watched Turtini (the team’s affectionate nickname for RoboTurtle) splash around in its pool. «We did a lot of motion capture, like the things they use in movies, because we need to develop those joints that it has,» he said.

This isn’t RoboTurtle’s first time at CES — it also appeared in 2025 as a static concept. This is the year, however, it’s found its fins, so to speak. Not only can it swim, but it can also respond to hand gestures: I throw it an OK gesture, and it dances in response. But as cute and limber as it is, RoboTurtle is a robot with an important mission.

RoboTurtle is an environmental research tool, built with input from researchers and NGOs, which can go where humans or other machines cannot for fear of disturbing complex and delicate underwater ecosystems, particularly coral reefs. It can move silently and naturally in a way that won’t scare wildlife, monitoring water quality and fish numbers with its built-in camera.

«One of the groups that we’re working with, they want to study the coral reefs in near Indonesia,» said Campo. «There was a very big incident over there with a boat that came up onto a coral reef and it disrupted the environment, [so] they want the least intrusive robot possible.»

The group wants to deploy RoboTurtle for certain periods every year to monitor the recovery of the coral and monitor the fish population, he added. Beatbot is currently training the built-in AI to give RoboTurtle monitoring and recognition skills.

At CES, I watched RoboTurtle paddle about only on the surface of the pool, but it can also dive down up to five meters. However, it needs to resurface to send data and its GPS signal back to base, much like a real turtle that needs to come to the surface to breathe. This also gives it a chance to recharge via the solar panel on its back.

Even though I was impressed with RoboTurtle’s swimming ability, Campo estimates that the Beatbot team is still a year and a half away from perfecting its technique, with the robot ready for full deployment in between three to five years.

CES 2026 is a show where tech with a real purpose feels scarce, so it sure is refreshing to see a company use its expertise to build something designed with a sustainable future in mind. It might be a while until we see RoboTurtle take to the seas, but I’m glad that I got to witness it at this stage of its journey.

Continue Reading

Trending

Copyright © Verum World Media